A health interview has a constraint no other kind does: a few imprecise words can turn a defensible statement into a regulatory problem. Overstating what a treatment does, implying a use beyond the approved indication, or characterizing trial results more strongly than the data supports are not just bad quotes. They can trigger a warning letter, a correction demanded by regulators, or a compliance investigation. And the people reading are often patients, for whom a spokesperson’s optimism is not a communications choice but a source of hope you are responsible for.
Regulatory and legal come first, not last
Before anyone drafts a talking point, sit down with regulatory affairs and legal and establish the boundaries: what can be said about the product, what claims the label supports, how trial data can be characterized, what is off-limits entirely. Their sign-off on the messages and the hard-question answers is a precondition for the interview, not a courtesy review afterward. If regulatory finds a problem with a quote after it has run, the options are all bad.
Precise language for data and claims
Every statement about what a treatment does needs to match the label and the published evidence, and be bounded to the population studied:
- Loose: “It works really well for patients with this condition.”
- Precise: “In the trial, which enrolled adults with moderate to severe disease, it met its primary endpoint, reducing [measure] by [amount] compared to placebo.”
Agree the exact phrasing for each claim in advance, and rehearse it, because under questioning the instinct is to simplify and the simplification is where the line gets crossed.
The patient-privacy line
The standing answer to any question about a specific individual is that you cannot discuss any person’s care, full stop. Confirming that someone is a patient is itself a disclosure. If a patient has agreed to be part of the story, get that consent documented, confirm exactly what they have agreed can be said, and keep the spokesperson’s comments inside that boundary. When in doubt, the spokesperson says less.
Prepare for the hope questions
“Could this be a cure?” “What do you say to families who are waiting?” A reporter asks these, and a patient advocate in the interview may ask them more pointedly. The wrong answers are dismissiveness (“it’s too early to speculate” delivered coldly) and false promise (“we’re very hopeful” with no bound). Rehearse the honest middle: acknowledge what people are hoping for, be clear about what the data does and does not yet show, and be specific about the timeline for more.
Rehearse against the simplifier
The characteristic pressure in a health interview is a reporter, often well-meaning, repeatedly trying to get a cleaner, stronger, more quotable version of your claim. “So it’s effective?” “So patients should ask their doctor about it?” Practice with someone playing that role until the spokesperson can hold the precise, bounded answer three times without drifting toward the simpler one the reporter wants.
Frequently asked questions
What makes a health interview different from any other?
The regulatory line runs through every answer. Overstating efficacy, implying a use the label does not cover, or characterizing trial data loosely can be a compliance violation, not just a bad quote. And the audience often includes patients whose hope you can raise irresponsibly.
How do I talk about a drug or device that is still in trials?
Describe what the study is testing and where it is in the process, not what you expect it to show. 'We're studying whether it reduces X, and we'll have Phase 3 data next year' is safe. 'We think this could be a breakthrough' is not.
Can a spokesperson discuss individual patients?
Only with explicit, documented consent, and even then carefully. Confirming that a specific person is a patient, or any detail about their condition, without consent is a privacy violation. The default answer is that you cannot discuss any individual's care.
How do I handle a reporter who wants a simple yes or no on 'does it work'?
Give the honest, bounded answer: 'For the population we studied, it met its primary endpoint, meaning X. We don't have data on [other groups] yet.' Resisting the pressure to simplify past what the data supports is the whole job.
Should legal and regulatory review the prep?
Yes, always, for anything involving a product, trial data, or a safety issue. The spokesperson's talking points and their answers to the hard questions should be signed off by regulatory and legal before the interview, not explained to them after.
Preparing for a health or science story? Press Prep builds the reporter brief and the likely questions, and lets you rehearse the precise, bounded answers against a persistent interviewer. See message development or crisis communications media training.